Semax

Semax is a synthetic heptapeptide with the sequence Met–Glu–His–Phe–Pro–Gly–Pro, described as an analogue of an ACTH(4–10) fragment rather than the full ACTH hormone. The FDA briefing distinguishes Semax free base and acetate forms; that distinction matters when reading a study or product record.

The manufacturer-hosted Peptogen 0.1% instruction describes a Russian prescription liquid nasal-drop product containing 1 mg/mL Semax and 50 mcg per product drop. For contrast, the cited Peptogen Selank label describes a Russian over-the-counter nasal-drop product. Neither label is a generic spray, injectable preparation or proof of U.S. approval.

Research spans healthy volunteers, people recovering from stroke and animal models. The sections below distinguish performance and rehabilitation findings from imaging and laboratory results.

Preclinical work supports interest in BDNF/TrkB signaling. In a rat hippocampus study, a single Semax exposure increased BDNF protein, TrkB phosphorylation and related mRNA measures, with more conditioned-avoidance responses. This is animal mechanism evidence, not a human dose or treatment result.

The 2020 imaging study assigned 52 healthy participants to separate Semax, Selank and placebo groups and measured resting-state functional connectivity at baseline and 5 and 20 minutes after exposure. That imaging signal is not a direct test of memory or when a person feels a benefit.

The Kaplan et al. 1996 pilot randomized 16 healthy male operators into 8 Semax and 8 placebo participants. The report described task-performance benefits after intranasal Semax, while spontaneous false responses also increased. It was a small, short performance study.

The Gusev et al. 2018 publisher report enrolled 110 adults in early or late rehabilitation after ischemic stroke. Semax-treated subgroups received the drug alongside rehabilitation, while other rehabilitation groups did not receive Semax. Authors reported higher plasma BDNF and improved Barthel functional recovery; the report does not describe placebo control or blinding.

Panikratova et al. 2020 measured resting-state connectivity in separate Semax, Selank and placebo groups. It did not test a Semax–Selank combination or establish a memory, attention or work-performance outcome.

Attention and task performance: The small Kaplan operator pilot reported a positive task-performance signal after intranasal Semax, but the same report noted more spontaneous false responses. It is an early signal, not a general focus guarantee.

Post-stroke rehabilitation: Gusev reported higher plasma BDNF and better Barthel recovery in Semax-treated rehabilitation subgroups compared with non-Semax rehabilitation groups. The disease setting and study design limit what can be inferred for other patients or healthy cognition.

Mechanistic and imaging interest: Rat BDNF/TrkB findings and the Panikratova connectivity study show why Semax remains under study. They do not establish dementia prevention or traumatic-brain-injury treatment.

Reported experiences: Anecdotal accounts describe clearer thinking or focus after use. These are experiences rather than controlled findings and do not show how often they occur or predict an individual response.

The sources do not establish a universal cognitive-use protocol. The Russian prescription 0.1% label describes a named liquid product at 1 mg/mL, with 50 mcg per product drop and a 400–900 mcg/day, 3–5-day first-half-of-day context for mental fatigue. Those numbers belong to that dropper product; they do not define a fine-mist spray or injectable preparation.

Study exposures were different: Kaplan used 1 mg intranasally on two workdays in its Semax arm, while Gusev used 1% nasal drops at 6,000 mcg/day in two 10-day courses separated by 20 days alongside rehabilitation. These are research contexts, not a general repeat-dose or cycling schedule.

The FDA briefing identified no human subcutaneous safety or pharmacokinetic data in its review. Nasal-drop concentration cannot be converted into an injection dose, and onset, duration and absorption are not established across products or devices.

The Russian prescription 0.1% nasal-drop label reports possible mild nasal irritation with prolonged use and lists product-specific restrictions involving pregnancy, lactation, acute mental states, disorders accompanied by anxiety and a history of seizures. It contraindicates use under age 7, and under age 18 in ophthalmological and neurosurgical practice. These restrictions are specific to the labeled product.

The FDA briefing discusses possible bleeding concerns from limited literature and potential immune reactions related to aggregation and impurities in proposed injectable or nasal-spray products. These concerns are not measured human event rates.

The human studies are small or indication-specific and do not answer years-long safety, tolerance, dependence or withdrawal across formulations. Product identity, active form, route and other medicines remain relevant to any safety discussion.

Semax is often discussed alongside Selank, but the 2020 imaging study used separate Semax, Selank and placebo groups rather than a combined regimen. It therefore cannot establish synergy, additive cognitive benefit or combined safety.

The sources reviewed here do not test Semax with Epithalon, Dihexa, BPC-157, MOTS-c, supplements or other nootropics. Those combinations may be discussed as hypotheses or anecdotes, but no tested protocol or interaction-free status should be inferred.